Pay in 4 interest-free payments of $5.18 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
While the most recent clinical trial shows favorable results for those with knee-focused osteoarthritis and obesity, researchers must continue their efforts in other areas of the population, such as those with knee osteoarthritis and lower BMIs
Gravina, S.A
Profiling of bile acids and activated receptor S1PR2 in gingival tissues of periodontitis patients
Roche reported positive Phase II topline data showing that its once-weekly dual glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor agonist CT-388 achieved substantial, sustained, and dose-dependent weight loss through 48 weeks Roche reported positive topline results from its Phase II clinical trial, CT388-103, evaluating CT-388, Roches investigational dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist being developed for the treatment of obesity
US$ 20.73
US$ 21.36
US$ 23.58
:max_bytes(150000):strip_icc()/benefits-of-glutathione-89457_final-01-502464fe91b2444285b0cccf8cb0a33c.png)
US$ 27.38
US$ 26.91
US$ 25.38
US$ 25.04
US$ 21.78
